NCT04096573View on ClinicalTrials.gov

Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2020

Primary Completion Date

November 30, 2021

Study Completion Date

August 31, 2022

Conditions
Ulcerative Colitis
Interventions
DRUG

LC51-0255

LC51-0255

DRUG

Placebo

Placebo

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT04096573 - Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis | Biotech Hunter | Biotech Hunter